The expansion is under a new contract funded entirely by Federal funds under an indefinite delivery/indefinite quantity ('IDIQ') contract awarded to ABL from
The new agreement builds on previous collaborations between Just - Evotec Biologics and ABL to design highly efficient manufacturing processes for broadly neutralising antibodies ('bNAbs') against HIV. Under the expanded relationship, Just - Evotec Biologics will develop a third bNAb and perform large-scale cGMP manufacturing campaigns for both this bNAb and a previously developed bNAb against HIV for a Phase I clinical study. Just - Evotec Biologics will also provide release and stability testing services.
Dr
Dr
According to the WHO, there are over 38 million individuals living with HIV worldwide. The development of safe and efficacious HIV-1 treatments and prevention strategies remains one of the highest priorities of the NIAID. This programme aims to supply clinical material to continue vital ongoing clinical trials worldwide.
No financial details of the agreement between Just - Evotec Biologics and ABL were disclosed.
ABOUT
A leading CDMO harnessing decades of pioneering science and manufacturing expertise to drive the development of innovative therapies and vaccines. ABL has over 60 years of experience working with diverse organizations-including industry, government, and academic entities-to support their quest in improving vaccines, public health ABL maintains GMP facilities meeting
ABOUT JUST - EVOTEC BIOLOGICS
Just - Evotec Biologics, wholly owned by
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'should,' 'target,' 'would' and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Tel: +49 160 7164389
Fax: +49 40 560 81 333
Email: gabriele.hansen@evotec.comvCard
Hinnerk Rohwedder
Tel: +49 151 40704843
(C) 2024 Electronic News Publishing, source